SOUTH
SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 2, 2023
/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX),
a clinical-stage pharmaceutical company focused on developing novel
therapies for the treatment of prostate cancer, today announced
that the Company will participate in a fireside chat at the
Guggenheim Healthcare Talks 5th Annual Oncology Conference in
New York City on Thursday, February 9, 2023, at 9:00 a.m. Eastern Time.
David R. Parkinson, President and
Chief Executive Officer of ESSA Pharma; Peter Virsik, ESSA's Chief Operating Officer;
and David S. Wood, ESSA's Chief
Financial Officer, will host and participate in one-on-one
meetings.
A live webcast of the presentation can be accessed in the
Investors/Events & Presentations section of ESSA's website at
www.essapharma.com. An archived replay of the event will be
available for 30 days.
About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company focused on
developing novel and proprietary therapies for the treatment of
patients with prostate cancer. For more information, please visit
www.essapharma.com and follow us on Twitter under @ESSAPharma.
View original
content:https://www.prnewswire.com/news-releases/essa-pharma-to-participate-in-the-guggenheim-healthcare-talks-5th-annual-oncology-conference-301737785.html
SOURCE ESSA Pharma Inc